Bladder Cancer Treatments
Find Bladder Cancer Treatments
Gemcitabine
What is Avgemsi (Gemcitabine)?
Approved To Treat
Related Clinical Trials
Summary: This Phase II clinical trial (investigates the efficacy of combining gemcitabine, a chemotherapy agent, with ivonescimab, a bispecific PD-1/VEGF antibody, in patients with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression following chemoimmunotherapy (CIT). Lung cancer remains the leading cause of cancer-related death globally, and treatment options after CIT fai...
Summary: The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (...
Summary: This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ch...
Related Latest Advances
Brand Information
- Hypersensitivity
- Schedule-Dependent Toxicity [
- Myelosuppression
- Severe Cutaneous Adverse Reactions
- Pulmonary Toxicity and Respiratory Failure
- Hemolytic Uremic Syndrome
- Hepatic Toxicity
- Exacerbation of Radiation Therapy Toxicity
- Capillary Leak Syndrome
- Posterior Reversible Encephalopathy Syndrome
- Transfusion requirements: Red blood cell transfusions (19%); platelet transfusions (<1%)
- Edema: Edema (13%), peripheral edema (20%), generalized edema (<1%)
- Flu-like symptoms: Fever, asthenia, anorexia, headache, cough, chills, myalgia, insomnia, rhinitis, sweating, and/or malaise (19%)
- Infection: Sepsis (<1%)
- Extravasation: Injection-site reactions (4%)
- Allergic: Bronchospasm (<2%); anaphylactoid reactions
- Blood and Lymphatic System: Thrombotic microangiopathy (TMA)
- Cardiovascular: Congestive heart failure, myocardial infarction, arrhythmias, supraventricular arrhythmias
- Vascular: Peripheral vasculitis, gangrene, capillary leak syndrome
- Skin: Cellulitis; pseudocellulitis; severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP); desquamation and bullous skin eruptions
- Hepatic: Hepatic failure, hepatic veno-occlusive disease
- Pulmonary: Interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, adult respiratory distress syndrome (ARDS), pulmonary eosinophilia
- Nervous System: Posterior reversible encephalopathy syndrome (PRES)

- 200 mg/5.26 mL (38 mg/mL), NDC 83831-122-01
- 1 g/26.3 mL (38 mg/mL), NDC 83831-123-01
- 2 g/52.6 mL (38 mg/mL), NDC 83831-124-01

(gemcitabine) Injection


(gemcitabine) Injection



